Dr. Scott R. May is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice. His broad scientific expertise spans many fields in the life sciences including mammalian genetics and genomics, neurobiology, development, molecular and cell biology, cardiovascular function, and virology. Scott applies this interdisciplinary knowledge to patent prosecution, freedom to operate and intellectual property matters for clients in the pharmaceutical, biotechnology, diagnostics, life sciences, and genomics industries.
Prior to joining the firm, Scott was a postdoctoral fellow in the laboratory of Dennis O’Leary at the Salk Institute for Biological Studies where he led research projects investigating transcription factors that regulate area-specific patterning of the cerebral cortex. During an earlier post-doctoral appointment at UCSF, Scott’s research focused on the mechanisms through which primary cilia transduce hedgehog signals as well as studying neural migration defects in mouse models of autism and schizophrenia.
Scott completed his Ph.D. in genetics from Duke University while conducting a forward genetic screen in mice to uncover novel mutations disrupting forebrain development and then positionally-cloning the affected genes. In addition to enabling Scott to hone his skills in bioinformatics, functional genetics, and cell and developmental biology, these mouse models opened avenues into foundational investigations of the underlying causes of neurodevelopmental and neurodegenerative diseases. Molecular therapeutic strategies were subsequently designed and tested in these models. As such, Scott has vast experience identifying molecular pathways and studying stem-cell patterning, cell migration, neural connectivity, and behavioral characterization within animal models of autism, schizophrenia, ciliopathies, lissencephaly, and seizure disorders.
Dr. Scott R. May is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice. His broad scientific expertise spans many fields in the life sciences including mammalian genetics and genomics, neurobiology, development, molecular and cell biology, cardiovascular function, and virology. Scott applies this interdisciplinary knowledge to patent prosecution, freedom to operate and intellectual property matters for clients in the pharmaceutical, biotechnology, diagnostics, life sciences, and genomics industries.
Prior to joining the firm, Scott was a postdoctoral fellow in the laboratory of Dennis O’Leary at the Salk Institute for Biological Studies where he led research projects investigating transcription factors that regulate area-specific patterning of the cerebral cortex. During an earlier post-doctoral appointment at UCSF, Scott’s research focused on the mechanisms through which primary cilia transduce hedgehog signals as well as studying neural migration defects in mouse models of autism and schizophrenia.
Scott completed his Ph.D. in genetics from Duke University while conducting a forward genetic screen in mice to uncover novel mutations disrupting forebrain development and then positionally-cloning the affected genes. In addition to enabling Scott to hone his skills in bioinformatics, functional genetics, and cell and developmental biology, these mouse models opened avenues into foundational investigations of the underlying causes of neurodevelopmental and neurodegenerative diseases. Molecular therapeutic strategies were subsequently designed and tested in these models. As such, Scott has vast experience identifying molecular pathways and studying stem-cell patterning, cell migration, neural connectivity, and behavioral characterization within animal models of autism, schizophrenia, ciliopathies, lissencephaly, and seizure disorders.
- Ph.D., Genetics, Duke University
Dissertation: “The Genetic Analysis of Forebrain and Cardiovascular Development in the Mouse”
- B.A., Biological Sciences, Oxford University
- Member, San Diego Intellectual Property Law Association
- U.S. Patent and Trademark Office
- Ph.D., Genetics, Duke University
Dissertation: “The Genetic Analysis of Forebrain and Cardiovascular Development in the Mouse”
- B.A., Biological Sciences, Oxford University
- Member, San Diego Intellectual Property Law Association
- U.S. Patent and Trademark Office
Select Publications
- Co-author, “Genetic mechanisms control the linear scaling between related cortical primary and higher order sensory areas,” (4) eLife e11416, December 2015
- Co-author, “A mutation in mouse Pak1ip1 causes orofacial clefting while human PAK1IP1 maps to 6p24 translocation breaking points associated with orofacial clefting,” 8(7) PLoS One e69333, July 2013
- Co-author, “Morphological defects in a novel Rdh10 mutant that has reduced retinoic acid biosynthesis and signaling,” 50(5) Genesis 415-23, May 2012
- Co-author, “A mutation in the pericentrin gene causes abnormal interneuron migration to the olfactory bulb in mice,” 340(1) Dev Biol. 41-53, January 2010
- Co-author, “The Rfx4 transcription factor modulates Shh signaling by regional control of ciliogenesis,” 2(95) Sci Signal. ra70, November 2009
- Co-author, “Retinoic acid from the meninges regulates cortical neuron generation,” 139(3) Cell 597-609, October 2009
- Co-author, “Cortical dysplasia and skull defects in mice with a Foxc1 allele reveal the role of meningeal differentiation in regulating cortical development,” 104(35) Proc Natl Acad Sci U S A. 14002-7, August 2007
- Co-author, “Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli,” 287(2) Dev Biol. 378-89, October 2005
- Co-author, “A focused and efficient genetic screening strategy in the mouse: identification of mutations that disrupt cortical development,” 2(8) PLoS Biol. E219, August 2004
- Co-author, “A Titin mutation defines roles for circulation in endothelial morphogenesis,” 270(1) Dev Biol. 31-46, June 2004
- Co-author, “The organizer factors Chordin and Noggin are required for mouse forebrain development,” 403(6770) Nature 658-61, February 2000
Select Publications
- Co-author, “Genetic mechanisms control the linear scaling between related cortical primary and higher order sensory areas,” (4) eLife e11416, December 2015
- Co-author, “A mutation in mouse Pak1ip1 causes orofacial clefting while human PAK1IP1 maps to 6p24 translocation breaking points associated with orofacial clefting,” 8(7) PLoS One e69333, July 2013
- Co-author, “Morphological defects in a novel Rdh10 mutant that has reduced retinoic acid biosynthesis and signaling,” 50(5) Genesis 415-23, May 2012
- Co-author, “A mutation in the pericentrin gene causes abnormal interneuron migration to the olfactory bulb in mice,” 340(1) Dev Biol. 41-53, January 2010
- Co-author, “The Rfx4 transcription factor modulates Shh signaling by regional control of ciliogenesis,” 2(95) Sci Signal. ra70, November 2009
- Co-author, “Retinoic acid from the meninges regulates cortical neuron generation,” 139(3) Cell 597-609, October 2009
- Co-author, “Cortical dysplasia and skull defects in mice with a Foxc1 allele reveal the role of meningeal differentiation in regulating cortical development,” 104(35) Proc Natl Acad Sci U S A. 14002-7, August 2007
- Co-author, “Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli,” 287(2) Dev Biol. 378-89, October 2005
- Co-author, “A focused and efficient genetic screening strategy in the mouse: identification of mutations that disrupt cortical development,” 2(8) PLoS Biol. E219, August 2004
- Co-author, “A Titin mutation defines roles for circulation in endothelial morphogenesis,” 270(1) Dev Biol. 31-46, June 2004
- Co-author, “The organizer factors Chordin and Noggin are required for mouse forebrain development,” 403(6770) Nature 658-61, February 2000
Biological Sciences and Biotechnology
- Antibody
- Biologics
- Cancer therapeutics
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Epigenetics
- Genetics
- Genomics
- Immuno-oncology
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Stem cell biology
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- Pharmacogenomics
Diagnostics and Medical Devices
- Bioinformatic
- Diagnostics
- Neuroimaging
- Point-of-care testing (POCT)
Chemistry and Material Science
- Protein engineering
Genomics and Data Analysis
- Functional genomics
Miscellaneous
- Design patent
- Fluorescence microscopy
Biological Sciences and Biotechnology
- Antibody
- Biologics
- Cancer therapeutics
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Epigenetics
- Genetics
- Genomics
- Immuno-oncology
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Stem cell biology
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- Pharmacogenomics
Diagnostics and Medical Devices
- Bioinformatic
- Diagnostics
- Neuroimaging
- Point-of-care testing (POCT)
Chemistry and Material Science
- Protein engineering
Genomics and Data Analysis
- Functional genomics
Miscellaneous
- Design patent
- Fluorescence microscopy
- Privacy Policy
- Terms of Use
- Accessibility